



MICI : nouvelles idées nouvelles thérapeutiques

Guillaume Savoye


Les MICI sont des maladies progressives...



Qu'il faut traiter précocement...





Pour éviter la destruction intestinale et l'invalidité associée



les anti-TNF rapidement diminuent la destruction intestinale



- 130 Crohn
 - Score de destruction intestinale




La cible dans les MICI

Rémission clinique


+




“le contrôle serré”




Etude CALM ou décider sur des biomarqueurs...



On fait mieux en prenant en compte les biomarqueurs en plus de la clinique...




Place de l'imagerie "proactive" dans le monitoring





Adapted from Danese S, Gut 2012 and Torres J et al. Lancet 2017


IL-12 and IL-23 et Crohn




Ustekinumab et Crohn

Réponse à 6 semaines

UNITI-1




UNITI-2



AMM: Bolus iv

Feagan B et al. NEJM 2016


Ustekinumab et Crohn: rémission à la 44^{ième} semaine





AMM: entretien sc toutes les 8 ou 12 semaines

Vedolizumab = Entyvio®

– Anti intégrine $\alpha 4 \beta 7$



Inhibition spécifique
interaction
 $\alpha 4 \beta 7$ /MADCAM1




• Entyvio® = Vedolizumab

RCH S52

AMM


et remboursement : RCH et Crohn

AMM
et remboursement : RCH et Crohn
Voie intraveineuse
Induction puis entretien 300 mg/8S




MC S6

MC S52



Feagan BG, N Engl J Med 2013;369(8):699–710
Sandborn WJ, N Eng J Med 2013;369:711–721.

L'arrivée des petites molécules par voie orale




Spadaccini M, et al. Int. J. Mol. Sci. 2017, 18, 1276

Sandborn WJ, et al. N Engl J Med 2016;374:1754–1762

Peyrin-Biroulet L, et al. Autoimmun Rev 2017;16:495–503.

Tofacitinib, inhibiteur panJAK: Phase III dans la RCH





Nom commercial Xeljanz

AMM et remboursement dans la PR

Sandborn W, et al. N Engl J Med 2017;376:1723–1736

Nouvelles approches : cellules souches

Des cellules souches d'origine graisseuses



conclusion

